4D Molecular Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2019 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
4D Molecular Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2019 to Q4 2022.
  • 4D Molecular Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2022 was $0.000, a 100% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $0 -$47K -100% Dec 31, 2022 10-K 2023-03-15
Q3 2022 $0 -$791K -100% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $0 -$1.22M -100% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $0 -$965K -100% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $47K -$1.44M -96.8% Dec 31, 2021 10-K 2023-03-15
Q3 2021 $791K Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $1.22M Jun 30, 2021 10-Q 2021-08-12
Q1 2021 $965K Mar 31, 2021 10-Q 2021-05-13
Q4 2020 $1.49M +$508K +51.9% Dec 31, 2020 10-K 2022-03-28
Q4 2019 $978K Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.